Final answer:
Epoprostenol, a beta agonist, cannot be administered by intraosseous infusion due to its potential to cause bone damage and its chemical instability in bone.
Step-by-step explanation:
One medication that cannot be administered by intraosseous infusion is epoprostenol, a beta agonist. Intraosseous infusion is a technique of injecting directly into the marrow of a bone to provide a non-collapsible entry point into the systemic venous system. This method is used when traditional IV access is difficult or impossible. Epoprostenol (Flolan) is a medication that is specifically contraindicated for intraosseous administration due to its chemical instability in solutions in contact with bone or its intense local vasoactive effects, which can lead to bone damage.
Intraosseous access is commonly used in emergency medicine when IV access is not feasible, and many medications, as well as fluids, blood products, and even some chemotherapeutic agents, can be administered via this route. However, since epoprostenol is contraindicated, alternate routes such as intravenous or inhalation would be considered for its administration.